title: Comorbidity, use of common medications, and risk of early death in patients with localized or locally advanced prostate cancer.
abstract: In this paper, we analyze predictive factors for early death from comorbidity (defined as death within 3 years from diagnosis and unrelated to prostate cancer) in patients with localized or locally advanced prostate cancer. Such information may guide individually tailored treatment or observation strategies, and help to avoid overtreatment. We retrospectively analyzed baseline parameters including information on comorbidity and medication use among 177 patients (median age at diagnosis 70 years). Actuarial survival analyses were performed. During the first 3 years, two patients (1.1%) died from progressive prostate cancer after they had developed distant metastases. The risk of dying from other causes (3.4%) was numerically higher, although not to a statistically significant degree. Six patients who died from other causes had age-adjusted Charlson comorbidity index (CCI) scores ≥5 (CCI is a sum score where each comorbid condition is assigned with a score depending on the risk of dying associated with this condition). The main comorbidity was cardiovascular disease. The two statistically significant predictive factors were medication use and age-adjusted CCI score ≥5 (univariate analysis). However, medication use was not an independent factor as all patients with age-adjusted CCI score ≥5 also used at least one class of medication. Median survival was 30 months in patients with age-adjusted CCI score ≥5. Prediction of non-prostate cancer death may be important to prevent overtreatment in patients who are more threatened by comorbidity. Our data suggest that simple parameters such as use of medications vs. none, or presence of serious cardiac disease vs. none, are not sufficient, and that age-adjusted CCI scores outperform the other factors included in our analysis.
authors.affiliation: Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway. carsten.nieder@nlsh.no
authors.forename: Carsten
authors.initials: C
authors.lastname: Nieder
authors.forename: Astrid
authors.initials: A
authors.lastname: Dalhaug
authors.forename: Adam
authors.initials: A
authors.lastname: Pawinski
authors.forename: Gro
authors.initials: G
authors.lastname: Aandahl
authors.forename: Jan
authors.initials: J
authors.lastname: Norum
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D015897:Comorbidity; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology / Q000517:prevention & control; D006331:Heart Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D061213:Mortality, Premature; D011471:Prostatic Neoplasms / Q000453:epidemiology* / Q000401:mortality / Q000628:therapy; D018570:Risk Assessment; D013997:Time Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal